Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Chiesi Group Company Profile

06:12 EDT 16th April 2014 | BioPortfolio

The Company, founded in Parma in 1935, is today an international reality in the pharmaceutical market. With global operations consisting of 21 direct affiliates, 3 manufacturing sites, and 3 research centres, the Group has over 2,700 employees, of whom 300 are involved in research and development activities.

Chiesi’s technologies and products are available in over 50 countries through a strategic alliances network of international pharmaceutical groups developed both on a global and local scale. Group turnover reached 565 million Euros in 2005. Historically, the continuous development of the Company has been based on strategic planning for innovation, internationalisation, socially compatible economical values, and use of effective organizational structures.

Chiesi's formula for success is based on a peculiar approach that allows to combine factors often thought of as opposites in the pharmaceutical industry – such as research and ethics, technology and humanity, commitment to results and concern for individuals, reliability and empathy – while encouraging innovation at all levels. The final goal is the creation of value through innovation.

Location

Chiesi Farmaceutici S.p.A.Via Palermo, 26/A,
Parma
43100
Italy

Contact

Phone: 39 0521 2791
Fax: 39 0521 774468
Email: info@chiesigroup.com


News Articles [222 Associated News Articles listed on BioPortfolio]

Chiesi publicly reprimanded

Chiesi has had the book thrown at it by the PMCPA and faces the shame of a public reprimand - its second in two years from the organisation which enforces the ABPI Code of Practice. The PMCPA will als...

Chiesi enters orphan drug space

Italian Chiesi Group has entered the orphan drug field by acquiring Danish Zymenex Holding.

Selvita, Chiesi Extend Chemistry Collaboration

Partnership’s success evolves in support of Chiesi pipeline

DOUBLE-DIGIT GROWTH AND INTERNATIONAL EXPANSION FOR THE CHIESI GROUP

PARMA, Italy, March 13, 2014 (GLOBE NEWSWIRE) -- Chiesi Farmaceutici SpA, a leading international pharmaceutical company focused in the respiratory, neonatology and special care therapeutic areas, cl...

Chiesi Farmaceutici Completes Acquisition of Cornerstone Therapeutics

PARMA, Italy and CARY, N.C., Feb. 4, 2014 /PRNewswire/ -- Chiesi Farmaceutici S.p.A. ("Chiesi"), a leading European pharmaceutical company, and Cornerstone Therapeutics Inc. (NASDAQ: CRTX) ("Cornersto...

Selvita S.A. Extends Long-Term Chemistry Collaboration with Chiesi Farmaceutici SpA

Krakow, Poland, January 10, 2014 / B3C newswire / - Selvita, Poland-based integrated drug discovery partner for the pharmaceutical and biotechnology industry, has extended its chemistry research ...

CereSpir, Chiesi deal

uniQure and Chiesi Announce Six Year Follow-up Data from Glybera(r) Treated Patients

AMSTERDAM, Netherlands, March 17, 2014 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leader in human gene therapy, and Chiesi Farmaceutici S.p.A. ("Chiesi"), a leading international pharmaceutic...

PubMed Articles [1967 Associated PubMed Articles listed on BioPortfolio]

The Ontogeny of the Motivation That Underlies In-Group Bias.

Humans demonstrate a clear bias toward members of their own group over members of other groups in a variety of ways. It has been argued that the motivation underlying this in-group bias in adults may...

The Attenuation of Lung Ischemia Reperfusion Injury by Oxymatrine.

To investigate the protective effects of oxymatrine (OMT) on lung ischemia reperfusion injury (LIRI) in rabbits, models of LIRI in rabbit were used. Thirty-two rabbits were randomly divided into four...

Isoflavone intake inhibits the development of 7,12-dimethylbenz(a)anthracene(DMBA)-induced mammary tumors in normal and ovariectomized rats.

To determine the associations between isoflavone (49.72% genistin, 5.32% daidzin, 34.54% glycitin) and breast cancer risk, 150 rats were given 5 mg 7,12-dimethylbenz(a)anthracene and half of them wer...

Group Psychotherapy in Psychiatric Residency Training.

Residents (n=114) in the department of psychiatry at the University of Toronto were surveyed in the spring of 1987 about their training in and attitudes about group psychotherapy. Significant interest...

Hematological Parameters and RBC TBARS Level of Q 10 Supplemented Tribal Sickle Cell Patients: A Hospital Based Study.

The study has been undertaken as number of sickle cell patients in Chhattisgarh tribal population is 23.7 %. The Co enzyme Q10 is a strong antioxidant and energy producing compound. The patients were...

Clinical Trials [1332 Associated Clinical Trials listed on BioPortfolio]

Efficacy and Tolerability of Beclomethasone Plus Salbutamol in HFA pMDI Fixed Combination vs Beclomethasone Plus Salbutamol in CFC pMDI Fixed Combination in a 12-week Treatment Period of Adult Patients With Uncontrolled Asthma

The purpose of this trial is to verify if the test treatment BDP 250 mcg/salbutamol 100 mcg HFA pMDI fixed combination is non-inferior to BDP 250 mcg/salbutamol 100 mcg pMDI fixed combina...

Does Cognitive Rehabilitation Demonstrate Benefits in the Group Setting With People Whom Have Experienced Brain Injury?

The purpose of this study is to determine whether there is benefit from providing cognitive rehabilitation in the group setting. Several standardized tools will be used to measure progres...

Short Term Group Therapy for OCD

Assessing OCD before and after group therapy

Psychological Prevention of Internalizing Disorders

The purpose of this study is to determine whether cognitive-behavioral group prevention (CBT-G) for german children is effective and to what extent parental group training moderates outcom...

Verification Study on Lafutidine in Mild Reflux Oesophagitis - Double Blind Controlled Study With Famotidine -

The purpose of the study is to verify superiority of the lafutidine group over the placebo group and non-inferiority to the famotidine group in terms of endoscopic healing rate of the pati...

Companies [1379 Associated Companies listed on BioPortfolio]

Chiesi Group

The Company, founded in Parma in 1935, is today an international reality in the pharmaceutical market. With global operations consisting of 21 direct affiliates, 3 manufacturing sites, and 3 research...

Chiesi Farmaceutici S.p.A.

Chiesi Pharmaceuticals, which started up in 1935 as a small family company is today an international company in the pharmaceutical sector and operates in all 5 continents with 24 direct branches, 3...

W2 Group, Inc.

W2 Group is a global marketing services ecosystem that helps CMOs in their new role as builders of communities and content aggregators. W2 Group companies, including Digital...

PharmEvo (Pvt.) Ltd.

PharmEvo is backed by a reputable corporate group with a history of successful business ventures spread over 30 years. The group made its debut in 1971, with the sales and marketing of prestigious bra...

ACE Group

Celebrating 25 years of insuring progress, the ACE Group is a global leader in insurance and reinsurance serving a diverse group of clients. Headed by ACE Limited (NYSE:ACE), a co...

More Information about "Chiesi Group" on BioPortfolio

We have published hundreds of Chiesi Group news stories on BioPortfolio along with dozens of Chiesi Group Clinical Trials and PubMed Articles about Chiesi Group for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Chiesi Group Companies in our database. You can also find out about relevant Chiesi Group Drugs and Medications on this site too.

Search BioPortfolio:
Advertisement

Corporate Database Quicklinks



Searches Linking to this Company Record

Advertisement